Bioactive compounds: Safety and efficacy (Consensus Meeting - Part II)

H.K. Biesalski; L.O. Dragsted; I. Elmadfa; R. Grossklaus; M.R. Müller; D. Schrenk; P. Walter; P. Weber

doi:10.1016/j.nut.2009.06.014

Bioactive compounds: Safety and efficacy (Consensus Meeting - Part II)

H.K. Biesalski
, L.O. Dragsted
, I. Elmadfa
, R. Grossklaus
, M.R. Müller
, D. Schrenk
, P. Walter
, P. Weber

Research output: Contribution to journal › Article › Academic › peer-review

40 Citations (Scopus)

Abstract

The efficacy and safety of bioactive compounds depend on a few known and unknown parameters. What is a physiologic dose and how can that dose be defined in cases of bioactive compounds with a poor knowledge of supply and distribution? What safety sets are needed? How can individual aspects such as polymorphisms or differences in absorption be considered? A group of experts tried to answer these and related questions during the 23rd Hohenheim Consensus Meeting at the University of Hohenheim in Stuttgart. (C) 2009 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	1206-1211
Journal	Nutrition
Volume	25
Issue number	11-12
DOIs	https://doi.org/10.1016/j.nut.2009.06.014
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

single-nucleotide polymorphisms
human genome
receptors
sequence
disease
diet

Access to Document

10.1016/j.nut.2009.06.014

Cite this

@article{78e794af4f424457862531c531bc0d2e,

title = "Bioactive compounds: Safety and efficacy (Consensus Meeting - Part II)",

abstract = "The efficacy and safety of bioactive compounds depend on a few known and unknown parameters. What is a physiologic dose and how can that dose be defined in cases of bioactive compounds with a poor knowledge of supply and distribution? What safety sets are needed? How can individual aspects such as polymorphisms or differences in absorption be considered? A group of experts tried to answer these and related questions during the 23rd Hohenheim Consensus Meeting at the University of Hohenheim in Stuttgart. (C) 2009 Elsevier Inc. All rights reserved.",

keywords = "single-nucleotide polymorphisms, human genome, receptors, sequence, disease, diet",

author = "H.K. Biesalski and L.O. Dragsted and I. Elmadfa and R. Grossklaus and M.R. M{\"u}ller and D. Schrenk and P. Walter and P. Weber",

year = "2009",

doi = "10.1016/j.nut.2009.06.014",

language = "English",

volume = "25",

pages = "1206--1211",

journal = "Nutrition",

issn = "0899-9007",

publisher = "Elsevier",

number = "11-12",

}

TY - JOUR

T1 - Bioactive compounds: Safety and efficacy (Consensus Meeting - Part II)

AU - Biesalski, H.K.

AU - Dragsted, L.O.

AU - Elmadfa, I.

AU - Grossklaus, R.

AU - Müller, M.R.

AU - Schrenk, D.

AU - Walter, P.

AU - Weber, P.

PY - 2009

Y1 - 2009

N2 - The efficacy and safety of bioactive compounds depend on a few known and unknown parameters. What is a physiologic dose and how can that dose be defined in cases of bioactive compounds with a poor knowledge of supply and distribution? What safety sets are needed? How can individual aspects such as polymorphisms or differences in absorption be considered? A group of experts tried to answer these and related questions during the 23rd Hohenheim Consensus Meeting at the University of Hohenheim in Stuttgart. (C) 2009 Elsevier Inc. All rights reserved.

AB - The efficacy and safety of bioactive compounds depend on a few known and unknown parameters. What is a physiologic dose and how can that dose be defined in cases of bioactive compounds with a poor knowledge of supply and distribution? What safety sets are needed? How can individual aspects such as polymorphisms or differences in absorption be considered? A group of experts tried to answer these and related questions during the 23rd Hohenheim Consensus Meeting at the University of Hohenheim in Stuttgart. (C) 2009 Elsevier Inc. All rights reserved.

KW - single-nucleotide polymorphisms

KW - human genome

KW - receptors

KW - sequence

KW - disease

KW - diet

U2 - 10.1016/j.nut.2009.06.014

DO - 10.1016/j.nut.2009.06.014

M3 - Article

SN - 0899-9007

VL - 25

SP - 1206

EP - 1211

JO - Nutrition

JF - Nutrition

IS - 11-12

ER -

Bioactive compounds: Safety and efficacy (Consensus Meeting - Part II)

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this